Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Liver Transplantation-Pipeline Review, H1 2015

Liver Transplantation-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Liver Transplantation-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Liver Transplantation-Pipeline Review, H1 2015', provides an overview of the Liver Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Transplantation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Liver Transplantation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Liver Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Liver Transplantation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Liver Transplantation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Liver Transplantation Overview 7

Therapeutics Development 8

Pipeline Products for Liver Transplantation-Overview 8

Pipeline Products for Liver Transplantation-Comparative Analysis 9

Liver Transplantation-Therapeutics under Development by Companies 10

Liver Transplantation-Therapeutics under Investigation by Universities/Institutes 11

Liver Transplantation-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Liver Transplantation-Products under Development by Companies 15

Liver Transplantation-Products under Investigation by Universities/Institutes 16

Liver Transplantation-Companies Involved in Therapeutics Development 17

Astellas Pharma Inc. 17

Conatus Pharmaceuticals Inc. 18

Digna Biotech, S.L. 19

Dompe Farmaceutici S.p.A. 20

Isogenis, Inc. 21

RedHill Biopharma Ltd. 22

Liver Transplantation-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

ABC-294640-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

cardiotrophin-1-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Cell Therapy for Liver Transplantation-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Cell Therapy for Liver Transplantation-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Cell Therapy for Liver Transplantation-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

emricasan-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Gene Therapy for High-Grade Glioma and Liver Transplantation-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

reparixin-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

tacrolimus ER-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Liver Transplantation-Recent Pipeline Updates 46

Liver Transplantation-Dormant Projects 52

Liver Transplantation-Dormant Projects 52

Liver Transplantation-Discontinued Products 53

Liver Transplantation-Product Development Milestones 54

Featured News & Press Releases 54

May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 54

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 54

Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 55

Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches 56

Jul 01, 2011: Astellas Introduces Advagraf In India 56

Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 57

Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant 57

Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe. 58

Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation 59

Apr 30, 2007: Advagraf Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation. 59

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

Number of Products under Development for Liver Transplantation, H1 2015 8

Number of Products under Development for Liver Transplantation-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Liver Transplantation-Pipeline by Astellas Pharma Inc., H1 2015 17

Liver Transplantation-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 18

Liver Transplantation-Pipeline by Digna Biotech, S.L., H1 2015 19

Liver Transplantation-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 20

Liver Transplantation-Pipeline by Isogenis, Inc., H1 2015 21

Liver Transplantation-Pipeline by RedHill Biopharma Ltd., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Mechanism of Action, H1 2015 27

Number of Products by Stage and Route of Administration, H1 2015 29

Number of Products by Stage and Molecule Type, H1 2015 31

Liver Transplantation Therapeutics-Recent Pipeline Updates, H1 2015 46

Liver Transplantation-Dormant Projects, H1 2015 52

Liver Transplantation-Discontinued Products, H1 2015 53

List of Figures

Number of Products under Development for Liver Transplantation, H1 2015 8

Number of Products under Development for Liver Transplantation-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29

Number of Products by Top 10 Molecule Types, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

Conatus Pharmaceuticals Inc.

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

Isogenis, Inc.

RedHill Biopharma Ltd.

Liver Transplantation Therapeutic Products under Development, Key Players in Liver Transplantation Therapeutics, Liver Transplantation Pipeline Overview, Liver Transplantation Pipeline, Liver Transplantation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com